Aprogen decides to acquire 10 billion won CB of subsidiary Aprogen Biologics
- Subsidiary Aprogen Biologics decides to issue 10 billion won of 19th unregistered unsecured private convertible bonds to parent Aprogen
- Conversion price: 4,433 won, coupon rate: 2%, yield to maturity: 4%, maturity: May 29, 2031
- Conversion shares: 2,255,808 (15.65% of subsidiary's total outstanding shares)
- Proceeds to be used for acquisition of securities of other corporation: 10 billion won investment in Akro New Technology Fund No. 241
- Subsidiary's outstanding CB total 128 billion won (including 118 billion won prior issues), convertible into 24,427,092 shares, representing 169.49% of current shares of 14,412,374
- Investment amount of 10 billion won is approximately 11.2% of Aprogen's market cap of 89.2 billion won
ADVERTISEMENT (250px+)
KOSPI Filing Information
- Filing: Major Event Report (Decision on Issuance of Convertible Bonds) (Major Management Matters of Subsidiary)
- Company: Aprogen (007460)
- Submission: Aprogen, Inc.
- Receipt: 05-21-2026
- Under KRX KOSPI Market Division